公开(公告)号：WO2019126352A1

公开(公告)日：2019-06-27

申请号：PCT/US2018/066545

申请日：2018-12-19

Applicant: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK

Inventor： JORNET, Josep ,  FENG, Liang ,  FURLANI, Edward, P. ,  GAN, Qiaoqiang ,  SUN, Zhi ,  WU, Yun

IPC: G01N21/55 ,  G01N21/17

CPC classification number: G01N21/553 ,  A61B5/0031 ,  A61B5/14546 ,  A61B5/14552 ,  A61B5/686 ,  A61B2562/0285

Abstract: A system is provided for advanced health monitoring and diagnosis based on wearable nano-biosensing networks. Nanophotonic and wireless communication technologies are synergistically leveraged to bridge the gap between nano-biosensing technologies and commercial wearable devices. Embodiments of the presently-disclosed system may include: (1) a nanoplasmonic biochip, implanted subcutaneously and built on a flexible substrate; (2) a nanophotonic smart band or wearable device that is able to collect in-vivo signals on-demand and relay them wirelessly to the user's smartphone by means of a secure data transfer; and (3) advanced signal processing techniques implemented on a remote processor to extract relevant data from the received signals and provide a diagnosis in real-time.

公开(公告)号：WO2019121450A1

公开(公告)日：2019-06-27

申请号：PCT/EP2018/085114

申请日：2018-12-17

Applicant: SANOFI

Inventor： KLEMM, Thomas

IPC: A61B5/145 ,  H02J5/00 ,  G01N33/66 ,  A61B5/021 ,  A61B5/1468 ,  A61B5/1477 ,  A61B5/00 ,  H02J7/00

CPC classification number: A61B5/14532 ,  A61B5/021 ,  A61B5/14546 ,  A61B5/1468 ,  A61B5/1477 ,  A61B5/4839 ,  A61B2560/0204 ,  A61B2560/0209 ,  A61B2560/0214 ,  H02J7/0047 ,  H02J50/10 ,  H02J2007/005

Abstract: The disclosure refers to a medical device (100) comprising • a measurement unit (110) adapted to measure a value of a physiological parameter, for example a blood glucose level, • an energy storage unit (190) connected with the measurement unit (110) providing energy supply for the measurement unit (110), · an NFC antenna (193), • an energy supply unit (195) connected to the NFC antenna (193) and to the energy storage unit (190), wherein the energy supply unit (195) controls the NFC antenna (193) such that in the presence of an electromagnetic field of a pre-defined frequency range energy is withdrawn from the electromagnetic field surrounding the NFC antenna (193) and stored in the energy storage unit (190), • a charge control unit (196, 196A), connected to the energy storage unit (190) and adapted to determine the electric charge contained in the energy storage unit (190), and a communication unit (160) connected with the charge control unit (195), wherein the communication unit (160) is adapted to output a pre-defined visible, audible and/or tactile signal if the electric charge contained in the energy storage unit (190) determined by the charge control unit (196, 196A) is equal to or below a pre-defined minimum charge value. The advantage of such medical device is that too low charge is avoided and thereby the risk of determination of false measurement values is reduced. The disclosure further refers to an operation method of a medical device (100).

公开(公告)号：WO2019114883A1

公开(公告)日：2019-06-20

申请号：PCT/DE2018/101015

申请日：2018-12-13

Applicant: SCHIKORA, Detlef ,  WEBER, Michael

Inventor： SCHIKORA, Detlef ,  WEBER, Michael

IPC: A61B5/00 ,  A61N5/06 ,  A61B5/145 ,  A61B5/1459

CPC classification number: A61B5/0071 ,  A61B5/0075 ,  A61B5/0086 ,  A61B5/14503 ,  A61B5/14546 ,  A61B5/1459 ,  A61B5/4836 ,  A61B5/6852 ,  A61B5/6876 ,  A61B2560/0431 ,  A61B2562/146 ,  A61N5/062 ,  A61N2005/0602 ,  A61N2005/0626 ,  A61N2005/0652 ,  A61N2005/0662

Abstract: Die vorliegende Erfindung betrifft eine Vorrichtung zur Registrierung von einzelnen Tumorzellen, Tumorzellenclustern und Mikrometastasen im Blutkreislauf, die mit einer photoempfindlichen Substanz angereichert sind. Aufgabe der Erfindung ist es, eine Vorrichtung zur Verfügung zu stellen, die sowohl die sichere diagnostische Erkennung einzelner Tumorzellen im Blutkreislauf von Menschen und Säugetieren als auch deren therapeutische in-situ-Eliminierung ermöglicht. Gelöst wird diese Aufgabe mit einer Vorrichtung die aufweist eine Strahlungsquelle (7, 11) mit intravasaler oder extravasaler Anregung der photoempfindlichen Substanz einen Detektor (1, 12, 13) mit intravasaler oder extravasaler Detektion einer Fluoreszenz- und/oder Phosphorenz- und/oder Lumineszenzstrahlung der angeregten Tumorzellen und/oder Tumorzellencluster und/oder Mikrometastasen ein mit dem Detektor (1, 12, 13) verbundenes Fluoreszenzspektrometer (5) hoher Empfindlichkeit zur Registrierung der emittierten Strahlung einen mit dem Spektrometer (5) verbundenen Computer (6), der die empfangenen Peaks der emittierten Strahlung als Funktion der Zeit aufzeichnet.

公开(公告)号：WO2019112895A1

公开(公告)日：2019-06-13

申请号：PCT/US2018/063290

申请日：2018-11-30

Applicant: ABBOTT DIABETES CARE INC.

Inventor： MITCHELL, Steven T. ,  FUJIMOTO, Frank David ,  CHO, Hyun Brian

IPC: A61B5/145

CPC classification number: A61B5/14503 ,  A61B5/145 ,  A61B5/14532 ,  A61B5/14546 ,  A61B5/683 ,  A61B5/6833 ,  A61B5/6849 ,  A61B2560/0412 ,  A61B2560/0443 ,  A61B2562/00

Abstract: On-body analyte sensors may be designed for extended wear to provide ongoing measurement of physiological analyte levels. However, on-body analyte sensors may be susceptible to damage or dislodgment during wear due to routine interactions that occur with one's surroundings. Guard rings may be adapted to protect on-body analyte sensors from such interactions. Guard rings may comprise an annular body comprising an inner perimeter face, an outer perimeter face, a top edge, and a bottom face adapted for contacting a tissue surface. The inner perimeter face is shaped to circumferentially surround a sensor housing of an on-body analyte sensor. At least a portion of the outer perimeter face defines a chamfered surface extending between the top face and the bottom face. Adhesive pads or strips may further be engaged with the guard rings and aid in securing the guard rings to a surface, such as skin.

公开(公告)号：WO2019106296A1

公开(公告)日：2019-06-06

申请号：PCT/FR2018/053033

申请日：2018-11-29

Applicant: BIOMERIEUX ,  ELKEM SILICONES FRANCE SAS ,  F.D.S. ,  FIBROLINE ,  HOSPICES CIVILS DE LYON ,  UNIVERSITE CLAUDE BERNARD LYON 1 ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  ECOLE NORMALE SUPERIEURE DE LYON ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

Inventor： ROZAND, Christine ,  DARDY, Aline ,  BERRAT, Fanny ,  MOINE, Caroline ,  SERRE, Philippe

IPC: C12M1/12 ,  C12M1/34 ,  C12Q1/14

CPC classification number: C12Q1/04 ,  A61B5/14507 ,  A61B5/14539 ,  A61B5/14546 ,  A61B5/1477 ,  A61B5/1486 ,  A61B5/445 ,  A61F13/00063 ,  C12Q1/14 ,  C12Q1/18

Abstract: La présente invention concerne un dispositif médical (1, 1') non implantable destiné à recouvrir les plaies et les lésions cutanées, comprenant un biocapteur (3E, 3E'), caractérisé en ce que ledit biocapteur (3E, 3E') comprend une pièce en matériau absorbant et hydrophile fixant, en surface et/ou dans son épaisseur, une composition de poudres agglomérées comprenant des particules d'éthylène-acétate de vinyle (EVA) ayant une surface en partie recouverte au moins d'un sel d'acide orthophosphorique et d'un indicateur visuel de croissance microbiologique. En particulier, le dispositif médical (1, 1') peut comprendre plusieurs couches afin de permettre le guidage d'un liquide. La présente invention concerne un procédé de préparation d'un tel dispositif médical (1, 1').

公开(公告)号：WO2019099052A1

公开(公告)日：2019-05-23

申请号：PCT/US2017/062834

申请日：2017-11-21

Applicant: OJAI RETINAL TECHNOLOGY, LLC

Inventor： LUTTRULL, Jeffrey K. ,  CHANG, David B.

IPC: A61B3/12

CPC classification number: A61B3/12 ,  A61B3/0008 ,  A61B5/0066 ,  A61B5/0082 ,  A61B5/14546 ,  A61B5/1455 ,  A61F9/00821 ,  A61F2009/00863

Abstract: A process for determining levels or concentrations of melanin within an eye includes generating first and second light beams of a different wavelength. The first and second light beams are applied into the eye, such as a retinal pigment epithelium and choroid of the eye. The amount of light reflected from the eye from the first light beam and the second light beam is measured, such as using a reflectometer. A level or concentration of the melanin within the eye is calculated using the measured amount of light reflected from the eye from the first and second light beams.

公开(公告)号：WO2019071138A1

公开(公告)日：2019-04-11

申请号：PCT/US2018/054627

申请日：2018-10-05

Applicant: AMERICAN UNIVERSITY OF BEIRUT

Inventor： COSTANTINE, Joseph ,  KANJ, Rouwaida ,  EID, Assaad

IPC: A61B5/145 ,  A61B5/05 ,  H01Q21/00 ,  H01Q1/27 ,  H01Q3/40

CPC classification number: A61B5/0024 ,  A61B5/0507 ,  A61B5/1451 ,  A61B5/14532 ,  A61B5/14546 ,  A61B2562/046 ,  H01Q1/2291 ,  H01Q1/273 ,  H01Q3/24 ,  H01Q3/26 ,  H01Q5/30 ,  H01Q7/00 ,  H01Q21/0037 ,  H01Q21/065 ,  H01Q21/20 ,  H01Q21/28

Abstract: The device measures glucose concentration in blood without any extraction of blood. The device is a non-invasive method for measuring glucose Radio Frequency and Antenna Circuits and Systems. The device is a wearable device that can non-invasively measure blood glucose levels in an instantaneous manner and continuous manner.

公开(公告)号：WO2019008601A1

公开(公告)日：2019-01-10

申请号：PCT/IN2018/050435

申请日：2018-07-03

Applicant: INDIAN INSTITUTE OF TECHNOLOGY MADRAS (IIT MADRAS)

Inventor： S, Dr.Ramaprabhu ,  P, Dr.Baraneedharan ,  ALEXANDER, Dr.Sheeba

IPC: C01B32/182

CPC classification number: C01B32/182 ,  A61B5/14532 ,  A61B5/14546 ,  A61B5/1468

Abstract: The invention relates to the preparation of novel Zn- SnO2 /NG hybrid nanocomposite material and its application in three component electrochemical detection simultaneously. A simple hydrothermal approach is used for preparation and the prepared products characterized by XRD, XPS, Raman, FE-SEM and HR-TEM for their structural, compositional and morphological properties. The multicomponent detection of Zn-SnO2 /NG hybrid nanocomposite modified GC exhibited good electrochemical redox behavior towards dopamine, cholesterol and glucose on same electrode. Further, the real time capability and reproducibility of hybrid nanocomposite in sensing dopamine, cholesterol and glucose showed exceptional performance with

公开(公告)号：WO2018167673A1

公开(公告)日：2018-09-20

申请号：PCT/IB2018/051675

申请日：2018-03-13

Applicant: MAGAGULA, Loretta Qinisile

Inventor： MAGAGULA, Loretta Qinisile

IPC: A61B5/15 ,  G01N33/569

CPC classification number: A61B5/150022 ,  A61B5/14514 ,  A61B5/14546 ,  A61B5/150099 ,  A61B5/150358 ,  A61B5/150389 ,  A61B5/150755 ,  A61B5/150862 ,  A61B5/150969 ,  A61B5/150984 ,  A61B5/15113 ,  A61B5/15117 ,  A61B5/15144 ,  A61B5/157 ,  A61B5/685 ,  A61B2562/0295 ,  A61B2562/242

Abstract: The invention relates to a medical test device and method, and more particularly, to a medical test device and method for sampling and testing a bodily fluid. The medical test device includes a housing (3) having a test sample extraction means (5), a buffer chamber (10) and a test means (15). The test sample and buffer are tested by the test means to display a visible result.

公开(公告)号：WO2018127372A1

公开(公告)日：2018-07-12

申请号：PCT/EP2017/082719

申请日：2017-12-13

Applicant: WITTEMAN, Johanna Cornelia Maria

Inventor： WITTEMAN, Johanna Cornelia Maria

IPC: G01N33/68 ,  A61B5/00 ,  G06F19/00

CPC classification number: G01N33/6893 ,  A61B5/02007 ,  A61B5/14546 ,  A61B5/7264 ,  A61B5/7275 ,  G01N2333/4712 ,  G01N2333/58 ,  G01N2800/324 ,  G01N2800/325 ,  G01N2800/50 ,  G01N2800/52 ,  G16H50/20 ,  G16H50/30 ,  G16Z99/00

Abstract: The present invention provides a method to assess troponin peaks in a subject to estimate CHD risk, said method comprising a) fine-temporal serial testing in body fluid samples obtained from the subject the concentration of troponin; b) assessment of troponin peaks in a subject, wherein preferably an accumulative peak score is computed, and whereby peak height and peak frequency are indicative for the risk of CHD in the subject; c) the troponin peaks are assessed and corresponding CHD risk computed in an ongoing fashion; d) a clinical algorithm is used to determine an increased CHD risk in the subject. The present invention also provides a method to use above method to select a suitable therapy against CHD for the subject, to monitor treatment effectiveness and to guide treatment course in a subject. In an alternative, the assessment of troponin peaks will be performed in combination with the assessment of NT-proBNP peaks to estimate CHD risk.